Global Multivalent Pneumococcal Conjugate Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Page: 91

Published Date: 05 May 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Multivalent Pneumococcal Conjugate Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Multivalent Pneumococcal Conjugate Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Multivalent Pneumococcal Conjugate Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Multivalent Pneumococcal Conjugate Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Multivalent Pneumococcal Conjugate Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Multivalent Pneumococcal Conjugate Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Multivalent Pneumococcal Conjugate Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Multivalent Pneumococcal Conjugate Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck Sharp & Dohme Corp, Pfizer, CanSino Bio, Serum Institute of India Pvt. Ltd. and Shanghai Weizhou Biotechnology Co., Ltd.. etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation
Multivalent Pneumococcal Conjugate Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    13 Price
    20 Price
    23 Price
    24 Price

Market segment by Application
    Hospital
    Outpatient Center
    Others

Major players covered
    Merck Sharp & Dohme Corp
    Pfizer
    CanSino Bio
    Serum Institute of India Pvt. Ltd.
    Shanghai Weizhou Biotechnology Co., Ltd.

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Multivalent Pneumococcal Conjugate Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Multivalent Pneumococcal Conjugate Vaccine, with price, sales, revenue and global market share of Multivalent Pneumococcal Conjugate Vaccine from 2018 to 2023.
Chapter 3, the Multivalent Pneumococcal Conjugate Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Multivalent Pneumococcal Conjugate Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Multivalent Pneumococcal Conjugate Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Multivalent Pneumococcal Conjugate Vaccine.
Chapter 14 and 15, to describe Multivalent Pneumococcal Conjugate Vaccine sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Multivalent Pneumococcal Conjugate Vaccine
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
        1.3.2 13 Price
        1.3.3 20 Price
        1.3.4 23 Price
        1.3.5 24 Price
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Hospital
        1.4.3 Outpatient Center
        1.4.4 Others
    1.5 Global Multivalent Pneumococcal Conjugate Vaccine Market Size & Forecast
        1.5.1 Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018 & 2022 & 2029)
        1.5.2 Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity (2018-2029)
        1.5.3 Global Multivalent Pneumococcal Conjugate Vaccine Average Price (2018-2029)

2 Manufacturers Profiles
    2.1 Merck Sharp & Dohme Corp
        2.1.1 Merck Sharp & Dohme Corp Details
        2.1.2 Merck Sharp & Dohme Corp Major Business
        2.1.3 Merck Sharp & Dohme Corp Multivalent Pneumococcal Conjugate Vaccine Product and Services
        2.1.4 Merck Sharp & Dohme Corp Multivalent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Merck Sharp & Dohme Corp Recent Developments/Updates
    2.2 Pfizer
        2.2.1 Pfizer Details
        2.2.2 Pfizer Major Business
        2.2.3 Pfizer Multivalent Pneumococcal Conjugate Vaccine Product and Services
        2.2.4 Pfizer Multivalent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Pfizer Recent Developments/Updates
    2.3 CanSino Bio
        2.3.1 CanSino Bio Details
        2.3.2 CanSino Bio Major Business
        2.3.3 CanSino Bio Multivalent Pneumococcal Conjugate Vaccine Product and Services
        2.3.4 CanSino Bio Multivalent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 CanSino Bio Recent Developments/Updates
    2.4 Serum Institute of India Pvt. Ltd.
        2.4.1 Serum Institute of India Pvt. Ltd. Details
        2.4.2 Serum Institute of India Pvt. Ltd. Major Business
        2.4.3 Serum Institute of India Pvt. Ltd. Multivalent Pneumococcal Conjugate Vaccine Product and Services
        2.4.4 Serum Institute of India Pvt. Ltd. Multivalent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates
    2.5 Shanghai Weizhou Biotechnology Co., Ltd.
        2.5.1 Shanghai Weizhou Biotechnology Co., Ltd. Details
        2.5.2 Shanghai Weizhou Biotechnology Co., Ltd. Major Business
        2.5.3 Shanghai Weizhou Biotechnology Co., Ltd. Multivalent Pneumococcal Conjugate Vaccine Product and Services
        2.5.4 Shanghai Weizhou Biotechnology Co., Ltd. Multivalent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Shanghai Weizhou Biotechnology Co., Ltd. Recent Developments/Updates

3 Competitive Environment: Multivalent Pneumococcal Conjugate Vaccine by Manufacturer
    3.1 Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Manufacturer (2018-2023)
    3.2 Global Multivalent Pneumococcal Conjugate Vaccine Revenue by Manufacturer (2018-2023)
    3.3 Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Manufacturer (2018-2023)
    3.4 Market Share Analysis (2022)
        3.4.1 Producer Shipments of Multivalent Pneumococcal Conjugate Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
        3.4.2 Top 3 Multivalent Pneumococcal Conjugate Vaccine Manufacturer Market Share in 2022
        3.4.2 Top 6 Multivalent Pneumococcal Conjugate Vaccine Manufacturer Market Share in 2022
    3.5 Multivalent Pneumococcal Conjugate Vaccine Market: Overall Company Footprint Analysis
        3.5.1 Multivalent Pneumococcal Conjugate Vaccine Market: Region Footprint
        3.5.2 Multivalent Pneumococcal Conjugate Vaccine Market: Company Product Type Footprint
        3.5.3 Multivalent Pneumococcal Conjugate Vaccine Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Multivalent Pneumococcal Conjugate Vaccine Market Size by Region
        4.1.1 Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2029)
        4.1.2 Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2029)
        4.1.3 Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Region (2018-2029)
    4.2 North America Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
    4.3 Europe Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
    4.4 Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
    4.5 South America Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
    4.6 Middle East and Africa Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)

5 Market Segment by Type
    5.1 Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
    5.2 Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Type (2018-2029)
    5.3 Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2029)

6 Market Segment by Application
    6.1 Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
    6.2 Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Application (2018-2029)
    6.3 Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2029)

7 North America
    7.1 North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
    7.2 North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
    7.3 North America Multivalent Pneumococcal Conjugate Vaccine Market Size by Country
        7.3.1 North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
        7.3.2 North America Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
        7.3.3 United States Market Size and Forecast (2018-2029)
        7.3.4 Canada Market Size and Forecast (2018-2029)
        7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe
    8.1 Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
    8.2 Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
    8.3 Europe Multivalent Pneumococcal Conjugate Vaccine Market Size by Country
        8.3.1 Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
        8.3.2 Europe Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
        8.3.3 Germany Market Size and Forecast (2018-2029)
        8.3.4 France Market Size and Forecast (2018-2029)
        8.3.5 United Kingdom Market Size and Forecast (2018-2029)
        8.3.6 Russia Market Size and Forecast (2018-2029)
        8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific
    9.1 Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
    9.2 Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
    9.3 Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Market Size by Region
        9.3.1 Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2029)
        9.3.2 Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2029)
        9.3.3 China Market Size and Forecast (2018-2029)
        9.3.4 Japan Market Size and Forecast (2018-2029)
        9.3.5 Korea Market Size and Forecast (2018-2029)
        9.3.6 India Market Size and Forecast (2018-2029)
        9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
        9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America
    10.1 South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
    10.2 South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
    10.3 South America Multivalent Pneumococcal Conjugate Vaccine Market Size by Country
        10.3.1 South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
        10.3.2 South America Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
        10.3.3 Brazil Market Size and Forecast (2018-2029)
        10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa
    11.1 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
    11.2 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
    11.3 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Market Size by Country
        11.3.1 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
        11.3.2 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
        11.3.3 Turkey Market Size and Forecast (2018-2029)
        11.3.4 Egypt Market Size and Forecast (2018-2029)
        11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
        11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics
    12.1 Multivalent Pneumococcal Conjugate Vaccine Market Drivers
    12.2 Multivalent Pneumococcal Conjugate Vaccine Market Restraints
    12.3 Multivalent Pneumococcal Conjugate Vaccine Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry
    12.5 Influence of COVID-19 and Russia-Ukraine War
        12.5.1 Influence of COVID-19
        12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain
    13.1 Raw Material of Multivalent Pneumococcal Conjugate Vaccine and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Multivalent Pneumococcal Conjugate Vaccine
    13.3 Multivalent Pneumococcal Conjugate Vaccine Production Process
    13.4 Multivalent Pneumococcal Conjugate Vaccine Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Multivalent Pneumococcal Conjugate Vaccine Typical Distributors
    14.3 Multivalent Pneumococcal Conjugate Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Merck Sharp & Dohme Corp Basic Information, Manufacturing Base and Competitors
    Table 4. Merck Sharp & Dohme Corp Major Business
    Table 5. Merck Sharp & Dohme Corp Multivalent Pneumococcal Conjugate Vaccine Product and Services
    Table 6. Merck Sharp & Dohme Corp Multivalent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 7. Merck Sharp & Dohme Corp Recent Developments/Updates
    Table 8. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 9. Pfizer Major Business
    Table 10. Pfizer Multivalent Pneumococcal Conjugate Vaccine Product and Services
    Table 11. Pfizer Multivalent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 12. Pfizer Recent Developments/Updates
    Table 13. CanSino Bio Basic Information, Manufacturing Base and Competitors
    Table 14. CanSino Bio Major Business
    Table 15. CanSino Bio Multivalent Pneumococcal Conjugate Vaccine Product and Services
    Table 16. CanSino Bio Multivalent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 17. CanSino Bio Recent Developments/Updates
    Table 18. Serum Institute of India Pvt. Ltd. Basic Information, Manufacturing Base and Competitors
    Table 19. Serum Institute of India Pvt. Ltd. Major Business
    Table 20. Serum Institute of India Pvt. Ltd. Multivalent Pneumococcal Conjugate Vaccine Product and Services
    Table 21. Serum Institute of India Pvt. Ltd. Multivalent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 22. Serum Institute of India Pvt. Ltd. Recent Developments/Updates
    Table 23. Shanghai Weizhou Biotechnology Co., Ltd. Basic Information, Manufacturing Base and Competitors
    Table 24. Shanghai Weizhou Biotechnology Co., Ltd. Major Business
    Table 25. Shanghai Weizhou Biotechnology Co., Ltd. Multivalent Pneumococcal Conjugate Vaccine Product and Services
    Table 26. Shanghai Weizhou Biotechnology Co., Ltd. Multivalent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 27. Shanghai Weizhou Biotechnology Co., Ltd. Recent Developments/Updates
    Table 28. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Manufacturer (2018-2023) & (K Units)
    Table 29. Global Multivalent Pneumococcal Conjugate Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
    Table 30. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 31. Market Position of Manufacturers in Multivalent Pneumococcal Conjugate Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
    Table 32. Head Office and Multivalent Pneumococcal Conjugate Vaccine Production Site of Key Manufacturer
    Table 33. Multivalent Pneumococcal Conjugate Vaccine Market: Company Product Type Footprint
    Table 34. Multivalent Pneumococcal Conjugate Vaccine Market: Company Product Application Footprint
    Table 35. Multivalent Pneumococcal Conjugate Vaccine New Market Entrants and Barriers to Market Entry
    Table 36. Multivalent Pneumococcal Conjugate Vaccine Mergers, Acquisition, Agreements, and Collaborations
    Table 37. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
    Table 38. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
    Table 39. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
    Table 40. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
    Table 41. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Region (2018-2023) & (US$/Unit)
    Table 42. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Region (2024-2029) & (US$/Unit)
    Table 43. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
    Table 44. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
    Table 45. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Type (2018-2023) & (USD Million)
    Table 46. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Type (2024-2029) & (USD Million)
    Table 47. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2023) & (US$/Unit)
    Table 48. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Type (2024-2029) & (US$/Unit)
    Table 49. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
    Table 50. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
    Table 51. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Application (2018-2023) & (USD Million)
    Table 52. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Application (2024-2029) & (USD Million)
    Table 53. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2023) & (US$/Unit)
    Table 54. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Application (2024-2029) & (US$/Unit)
    Table 55. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
    Table 56. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
    Table 57. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
    Table 58. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
    Table 59. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
    Table 60. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
    Table 61. North America Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
    Table 62. North America Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
    Table 63. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
    Table 64. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
    Table 65. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
    Table 66. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
    Table 67. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
    Table 68. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
    Table 69. Europe Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
    Table 70. Europe Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
    Table 71. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
    Table 72. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
    Table 73. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
    Table 74. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
    Table 75. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
    Table 76. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
    Table 77. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
    Table 78. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
    Table 79. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
    Table 80. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
    Table 81. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
    Table 82. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
    Table 83. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
    Table 84. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
    Table 85. South America Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
    Table 86. South America Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
    Table 87. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
    Table 88. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
    Table 89. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
    Table 90. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
    Table 91. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
    Table 92. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
    Table 93. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
    Table 94. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
    Table 95. Multivalent Pneumococcal Conjugate Vaccine Raw Material
    Table 96. Key Manufacturers of Multivalent Pneumococcal Conjugate Vaccine Raw Materials
    Table 97. Multivalent Pneumococcal Conjugate Vaccine Typical Distributors
    Table 98. Multivalent Pneumococcal Conjugate Vaccine Typical Customers
List of Figures
    Figure 1. Multivalent Pneumococcal Conjugate Vaccine Picture
    Figure 2. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Type in 2022
    Figure 4. 13 Price Examples
    Figure 5. 20 Price Examples
    Figure 6. 23 Price Examples
    Figure 7. 24 Price Examples
    Figure 8. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 9. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Application in 2022
    Figure 10. Hospital Examples
    Figure 11. Outpatient Center Examples
    Figure 12. Others Examples
    Figure 13. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 14. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 15. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity (2018-2029) & (K Units)
    Figure 16. Global Multivalent Pneumococcal Conjugate Vaccine Average Price (2018-2029) & (US$/Unit)
    Figure 17. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Manufacturer in 2022
    Figure 18. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Manufacturer in 2022
    Figure 19. Producer Shipments of Multivalent Pneumococcal Conjugate Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
    Figure 20. Top 3 Multivalent Pneumococcal Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2022
    Figure 21. Top 6 Multivalent Pneumococcal Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2022
    Figure 22. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
    Figure 23. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
    Figure 24. North America Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 25. Europe Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 26. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 27. South America Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 28. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
    Figure 29. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
    Figure 30. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Type (2018-2029)
    Figure 31. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2029) & (US$/Unit)
    Figure 32. Global Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
    Figure 33. Global Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Application (2018-2029)
    Figure 34. Global Multivalent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2029) & (US$/Unit)
    Figure 35. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
    Figure 36. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
    Figure 37. North America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
    Figure 38. North America Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
    Figure 39. United States Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 40. Canada Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 41. Mexico Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 42. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
    Figure 43. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
    Figure 44. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
    Figure 45. Europe Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
    Figure 46. Germany Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 47. France Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 48. United Kingdom Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 49. Russia Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 50. Italy Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 51. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
    Figure 52. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
    Figure 53. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
    Figure 54. Asia-Pacific Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
    Figure 55. China Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 56. Japan Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 57. Korea Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 58. India Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 59. Southeast Asia Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 60. Australia Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 61. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
    Figure 62. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
    Figure 63. South America Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
    Figure 64. South America Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
    Figure 65. Brazil Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 66. Argentina Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 67. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
    Figure 68. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
    Figure 69. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
    Figure 70. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
    Figure 71. Turkey Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 72. Egypt Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 73. Saudi Arabia Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 74. South Africa Multivalent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 75. Multivalent Pneumococcal Conjugate Vaccine Market Drivers
    Figure 76. Multivalent Pneumococcal Conjugate Vaccine Market Restraints
    Figure 77. Multivalent Pneumococcal Conjugate Vaccine Market Trends
    Figure 78. Porters Five Forces Analysis
    Figure 79. Manufacturing Cost Structure Analysis of Multivalent Pneumococcal Conjugate Vaccine in 2022
    Figure 80. Manufacturing Process Analysis of Multivalent Pneumococcal Conjugate Vaccine
    Figure 81. Multivalent Pneumococcal Conjugate Vaccine Industrial Chain
    Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 83. Direct Channel Pros & Cons
    Figure 84. Indirect Channel Pros & Cons
    Figure 85. Methodology
    Figure 86. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Merck Sharp & Dohme Corp
Pfizer
CanSino Bio
Serum Institute of India Pvt. Ltd.
Shanghai Weizhou Biotechnology Co., Ltd.

Related Reports

Global Multivalent Pneumococcal Conjugate Vaccine Supply, Demand and Key Producers, 2023-2029

Global Multivalent Pneumococcal Conjugate Vaccine Supply, Demand and Key Producers, 2023-2029

date 05 May 2023

date Pharma & Healthcare

The global Multivalent Pneumococcal Conjugate Vaccine market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Multivalent Pneumococcal Conjugate Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Multivalent Pneumococcal Conjugate Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 18 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Multivalent Pneumococcal Conjugate Vaccine market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

Multivalent Pneumococcal Conjugate Vaccine

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>